Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

被引：5

作者：

Berenson, James R.

Klein, Leonard M.

Rifkin, Robert M.

Patel, Priti

Dixon, Sandra

Ou, Ying

Cartmell, Alan

机构：

[1] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA

[2] Illinois Canc Specialists, Niles, IL USA

[3] US Oncol Res Inc, Denver, CO USA

[4] Onyx Pharmaceut Inc, San Francisco, CA USA

[5] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8594

引用

页数：1